The effect of autologous conditioned serum on radiculopathy caused by herniated intervertebral disc

Investigation the effect of autologous conditioned serum (Orthokine) injection into the disc and intervertebral foramen on low back pain with radiculopathy caused by herniated intervertebral disc of the lumbar spine

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043923N3

Enrollment

Registered

2019-07-24

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radioculopathy caused by lumbar disc herniation. Intervertebral disc disorders with radiculopathy, lumbar region

Interventions

Intervention 1: Intervention group 1: Intradisc injection of 2 milliliter autologous conditioned serum following the fluoroscopy procedure after the injection of a safe contrast agent and approved pla

he will also check the returned medications. Intervention 2: Intervention group 2: Foramenal injection of 2 milliliter autologous conditioned serum following the fluoroscopy procedure after the inject

Eligibility

Sex/Gender

All

Age

19 Years to 70 Years

Inclusion criteria

Inclusion criteria: Having a herniated disc between the lumbar vertebra confirmed by a magnetic resonance imaging Low back pain score between 40 and 80 points on the 100-mm pain visual analogue scale

Exclusion criteria

Exclusion criteria: Bleeding disorders Drug addiction Drug sensitivity Psychopathy History of surgery on spin The lack of progressive motor weakness in the affected limb

Design outcomes

Primary

Measure	Time frame
Low back pain intensity within the past week. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: 100-mm visual analogue scale for low back pain.;Intensity of radiating pain in the lower extremities. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: 100-mm visual analogue scale for radiating pain.;Frequency of pain per day. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: Self-reported.	—

Measure

Time frame

Low back pain intensity within the past week. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: 100-mm visual analogue scale for low back pain.;Intensity of radiating pain in the lower extremities. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: 100-mm visual analogue scale for radiating pain.;Frequency of pain per day. Timepoint: Pre-trial screening and at week 0 (baseline), 1, 2, 3 and 4 (follow-up sessions). Method of measurement: Self-reported.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDawood Aghamohammadi

Tabriz University of Medical Sciences

daghamohamadi@yahoo.com+98 41 3336 1928

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026